Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1407

1.

Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems.

Rosenholm JM, Peuhu E, Eriksson JE, Sahlgren C, Lindén M.

Nano Lett. 2009 Sep;9(9):3308-11. doi: 10.1021/nl901589y.

PMID:
19736973
2.

Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.

Lu J, Liong M, Zink JI, Tamanoi F.

Small. 2007 Aug;3(8):1341-6. No abstract available.

PMID:
17566138
3.

Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery.

Chen C, Geng J, Pu F, Yang X, Ren J, Qu X.

Angew Chem Int Ed Engl. 2011 Jan 24;50(4):882-6. doi: 10.1002/anie.201005471. No abstract available.

PMID:
21246683
4.

Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.

Slowing II, Vivero-Escoto JL, Wu CW, Lin VS.

Adv Drug Deliv Rev. 2008 Aug 17;60(11):1278-88. doi: 10.1016/j.addr.2008.03.012. Review.

PMID:
18514969
5.

Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging.

Kumar R, Roy I, Ohulchanskyy TY, Goswami LN, Bonoiu AC, Bergey EJ, Tramposch KM, Maitra A, Prasad PN.

ACS Nano. 2008 Mar;2(3):449-56. doi: 10.1021/nn700370b.

PMID:
19206569
6.

Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors.

Rosenholm JM, Peuhu E, Bate-Eya LT, Eriksson JE, Sahlgren C, Lindén M.

Small. 2010 Jun 6;6(11):1234-41. doi: 10.1002/smll.200902355.

PMID:
20486218
7.

Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells.

Liu HM, Wu SH, Lu CW, Yao M, Hsiao JK, Hung Y, Lin YS, Mou CY, Yang CS, Huang DM, Chen YC.

Small. 2008 May;4(5):619-26. doi: 10.1002/smll.200700493.

PMID:
18491363
8.

Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges.

Rosenholm JM, Sahlgren C, Lindén M.

Nanoscale. 2010 Oct;2(10):1870-83. doi: 10.1039/c0nr00156b. Review.

PMID:
20730166
9.

Intracellular degradation of multilabeled poly(ethylene imine)-mesoporous silica-silica nanoparticles: implications for drug release.

Bergman L, Kankaanpää P, Tiitta S, Duchanoy A, Li L, Heino J, Lindén M.

Mol Pharm. 2013 May 6;10(5):1795-803. doi: 10.1021/mp3005879.

PMID:
23510188
10.

Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage.

Rosenholm JM, Mamaeva V, Sahlgren C, Lindén M.

Nanomedicine (Lond). 2012 Jan;7(1):111-20. doi: 10.2217/nnm.11.166. Review.

PMID:
22191780
11.

Mesoporous silica nanoparticles for intracellular controlled drug delivery.

Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS.

Small. 2010 Sep 20;6(18):1952-67. doi: 10.1002/smll.200901789. Review.

PMID:
20690133
12.

Targeting of porous hybrid silica nanoparticles to cancer cells.

Rosenholm JM, Meinander A, Peuhu E, Niemi R, Eriksson JE, Sahlgren C, Lindén M.

ACS Nano. 2009 Jan 27;3(1):197-206. doi: 10.1021/nn800781r.

PMID:
19206267
13.

Cell-induced intracellular controlled release of membrane impermeable cysteine from a mesoporous silica nanoparticle-based drug delivery system.

Mortera R, Vivero-Escoto J, Slowing II, Garrone E, Onida B, Lin VS.

Chem Commun (Camb). 2009 Jun 14;(22):3219-21. doi: 10.1039/b900559e.

PMID:
19587919
14.

Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery.

Zhao Y, Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS.

Expert Opin Drug Deliv. 2010 Sep;7(9):1013-29. doi: 10.1517/17425247.2010.498816. Review.

PMID:
20716017
15.

The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent.

Guo R, Li LL, Zhao WH, Chen YX, Wang XZ, Fang CJ, Feng W, Zhang TL, Ma X, Lu M, Peng SQ, Yan CH.

Nanoscale. 2012 Jun 7;4(11):3577-83. doi: 10.1039/c2nr30425b.

PMID:
22543578
16.

Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery.

Mandal BB, Kundu SC.

Nanotechnology. 2009 Sep 2;20(35):355101. doi: 10.1088/0957-4484/20/35/355101.

PMID:
19671963
17.

Structurally ordered mesoporous carbon nanoparticles as transmembrane delivery vehicle in human cancer cells.

Kim TW, Chung PW, Slowing II, Tsunoda M, Yeung ES, Lin VS.

Nano Lett. 2008 Nov;8(11):3724-7. doi: 10.1021/nl801976m.

PMID:
18954128
18.

Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles.

Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, Kim Y, Park JH, Kim J, Her S, Oh YK, Kwon IC, Kim K, Jeong SY.

J Control Release. 2009 May 5;135(3):259-67. doi: 10.1016/j.jconrel.2009.01.018.

PMID:
19331853
19.

Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with "saccharides".

Bernardos A, Mondragon L, Aznar E, Marcos MD, Martinez-Mañez R, Sancenon F, Soto J, Barat JM, Perez-Paya E, Guillem C, Amoros P.

ACS Nano. 2010 Nov 23;4(11):6353-68. doi: 10.1021/nn101499d.

PMID:
20958020
20.

Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery.

Bale SS, Kwon SJ, Shah DA, Banerjee A, Dordick JS, Kane RS.

ACS Nano. 2010 Mar 23;4(3):1493-500. doi: 10.1021/nn901586e.

PMID:
20201555
Items per page

Supplemental Content

Support Center